HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ryan, P. J. Articles by Fogelman, I. Search for Related Content PubMed PubMed Citation Articles by Ryan, P. J. Articles by Fogelman, I.

Bone Scintigraphy Following Intravenous Pamidronate for Paget's Disease of Bone

Departments of Nuclear Medicine and Rheumatology, Guy's Hospital, London, United Kingdom

Correspondence: For reprints contact: Dr. P.J. Ryan, Department of Nuclear Medicine, Guy's Hospital, St. Thomas Street, London, SE1 9RT, UK.

ABSTRACT

Pamidronate is one of several powerful bisphosphonates able to produce prolonged remissions of Paget's disease. This study examined to what extent bone scan changes parallel the clinical response and whether there is variability in the behavior of individual lesions. Twenty-five patients with pagetic bone pain for more than 2 yr were examined with bone scintigraphy before and on average 8 mo after six 30-mg infusions of pamidronate given weekly. Serum alkaline phosphatase and urinary hydroxyproline-to-creatinine ratios were measured before and 6 mo after treatment. A second course of pamidronate was given to 13 patients who had clinical or biochemical relapse. Of 136 pagetic lesions, 13 (10%) completely resolved, 90 (65%) improved and 33 (24%) remained unchanged. There was no significant difference in response between bony sites, although less active lesions were more likely to resolve completely. In conclusion pamidronate has a powerful effect on bone scan appearances in Paget's disease. Most lesions improve but complete resolution is uncommon. Less active lesions are more likely to resolve and are less likely to require further therapy.

This article has been cited by other articles:

				J. Installe, A. Nzeusseu, A. Bol, G. Depresseux, J.-P. Devogelaer, and M. Lonneux 18F-Fluoride PET for Monitoring Therapeutic Response in Paget's Disease of Bone J. Nucl. Med., October 1, 2005; 46(10): 1650 - 1658. [Abstract] [Full Text] [PDF]

				J. Donath, M. Krasznai, B. Fornet, P. Gergely Jr., and G. Poor Effect of bisphosphonate treatment in patients with Paget's disease of the skull Rheumatology, January 1, 2004; 43(1): 89 - 94. [Abstract] [Full Text] [PDF]

				J. A. Carrasquillo, M. Whatley, V. Dyer, W. D. Figg, and W. Dahut Alendronate Does Not Interfere with 99mTc-Methylene Diphosphonate Bone Scanning J. Nucl. Med., September 1, 2001; 42(9): 1359 - 1363. [Abstract] [Full Text] [PDF]